Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience

• Published in: Journal of cardiovascular magnetic resonance Vol. 14; no. 1; pp. 61 - 64
• Main Authors: Kellman, Peter, Wilson, Joel R, Xue, Hui, Bandettini, W Patricia, Shanbhag, Sujata M, Druey, Kirk M, Ugander, Martin, Arai, Andrew E
• Format: Journal Article
• Language: English
• Published: London Elsevier Inc 11.09.2012; BioMed Central; BioMed Central Ltd; Elsevier
• Subjects: Adult; Aged; Amyloidosis; Angiology; Cardiac patients; Cardiology; Diagnosis; Diffusion; Dilated cardiomyopathy; Edema; Elevated; Female; Fibrosis; Follow-Up Studies; Gadolinium; Heart attack; Heart diseases; Heart Diseases - pathology; Humans; Hypertrophic cardiomyopathy; Imaging; Leaks; Magnetic resonance; Magnetic resonance imaging; Magnetic Resonance Imaging, Cine - methods; Male; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Middle Aged; Myocardial infarction; Myocarditis; Myocardium - pathology; Patients; Radiology; Retrospective Studies; Systemic capillary leak syndrome; Volume fraction; United States; Sweden; Myocardial infarction; Myocarditis; Edema; Systemic capillary leak syndrome; Dilated cardiomyopathy; Fibrosis; Hypertrophic cardiomyopathy; Gadolinium
• ISSN: 1097-6647; 1532-429X; 1532-429X
• DOI: 10.1186/1532-429X-14-64

Diffuse myocardial fibrosis, and to a lesser extent global myocardial edema, are important processes in heart disease which are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using conventional late gadolinium enhancement (LGE) or T1-mapping. Measurement of the myocardial extracellular volume fraction (ECV) circumvents factors that confound T1-weighted images or T1-maps. We hypothesized that quantitative assessment of myocardial ECV would be clinically useful for detecting both focal and diffuse myocardial abnormalities in a variety of common and uncommon heart diseases. A total of 156 subjects were imaged including 62 with normal findings, 33 patients with chronic myocardial infarction (MI), 33 with hypertrophic cardiomyopathy (HCM), 15 with non-ischemic dilated cardiomyopathy (DCM), 7 with acute myocarditis, 4 with cardiac amyloidosis, and 2 with systemic capillary leak syndrome (SCLS). Motion corrected ECV maps were generated automatically from T1-maps acquired pre- and post-contrast calibrated by blood hematocrit. Abnormally-elevated ECV was defined as >2SD from the mean ECV in individuals with normal findings. In HCM the size of regions of LGE was quantified as the region >2 SD from remote. Mean ECV of 62 normal individuals was 25.4 ± 2.5% (m ± SD), normal range 20.4%-30.4%. Mean ECV within the core of chronic myocardial infarctions (without MVO) (N = 33) measured 68.5 ± 8.6% (p < 0.001 vs normal). In HCM, the extent of abnormally elevated ECV correlated to the extent of LGE (r = 0.72, p < 0.001) but had a systematically greater extent by ECV (mean difference 19 ± 7% of slice). Abnormally elevated ECV was identified in 4 of 16 patients with non-ischemic DCM (38.1 ± 1.9% (p < 0.001 vs normal) and LGE in the same slice appeared “normal” in 2 of these 4 patients. Mean ECV values in other disease entities ranged 32-60% for cardiac amyloidosis (N = 4), 40-41% for systemic capillary leak syndrome (N = 2), and 39-56% within abnormal regions affected by myocarditis (N = 7). ECV mapping appears promising to complement LGE imaging in cases of more homogenously diffuse disease. The ability to display ECV maps in units that are physiologically intuitive and may be interpreted on an absolute scale offers the potential for detection of diffuse disease and measurement of the extent and severity of abnormal regions.